Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is scheduled to present at the Seventh Annual Needham Biotechnology & Medical Technology Conference at the New York Palace Hotel in New York City on June 11, 2008, 11:00 a.m. Eastern Time.

A live audio webcast of this presentation will be accessible on the Company’s website at www.optimerpharma.com [1], under the investors section. A replay of this presentation will be available at the same location for thirty days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information regarding Optimer can be found at http://www.optimerpharma.com [2].